A phase II trial of iproplatin (CHIP) in previously treated advanced breast cancer.

Abstract

Iproplatin (CHIP) was administered to 35 previously treated women with metastatic adenocarcinoma of the breast. The drug was given at a dose of 45 mg/m2 intravenously for 5 consecutive days and was repeated every 28 days. In this trial, there was one partial response and two patients with stable disease out of 29 evaluable patients. The median duration of response in patients with either a partial response or stable disease was 4.8 months. Myelosuppression was the major toxicity, 11 patients had severe thrombocytopenia and 3 severe neutropenia. Mild renal insufficiency, anemia, and nausea and vomiting were also noted. Iproplatin has limited activity in heavily pretreated women with advanced breast carcinoma; further studies in patients less heavily treated may show an improved response rate.

• Authors: D J Meisner, S Ginsberg, A Ditch, A Louie, N Newman, R Comis, B Poiesz
• Journal: American journal of clinical oncology (Am J Clin Oncol) Vol. 12 Issue 2 Pg. 129-31 (Apr 1989) ISSN: 0277-3732 [Print] United States
• PMID: 2705402 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antineoplastic Agents
• Organoplatinum Compounds
• iproplatin

Topics

• Adenocarcinoma (drug therapy, secondary)
• Antineoplastic Agents (adverse effects, therapeutic use)
• Breast Neoplasms (drug therapy)
• Drug Evaluation
• Female
• Humans
• Middle Aged
• Neoplasm Metastasis
• Organoplatinum Compounds (adverse effects, therapeutic use)
• Remission Induction
• Thrombocytopenia (chemically induced)